MX2018008350A - Moduladores de 5´-nucleotidasa, ecto y el uso de los mismos. - Google Patents

Moduladores de 5´-nucleotidasa, ecto y el uso de los mismos.

Info

Publication number
MX2018008350A
MX2018008350A MX2018008350A MX2018008350A MX2018008350A MX 2018008350 A MX2018008350 A MX 2018008350A MX 2018008350 A MX2018008350 A MX 2018008350A MX 2018008350 A MX2018008350 A MX 2018008350A MX 2018008350 A MX2018008350 A MX 2018008350A
Authority
MX
Mexico
Prior art keywords
nucleotidase
ecto
compounds
modulators
disorders
Prior art date
Application number
MX2018008350A
Other languages
English (en)
Spanish (es)
Inventor
Kalisiak Jaroslaw
Pierre Paul Debien Laurent
Carlos Jaen Juan
V Lawson Kenneth
Reddy Leleti Manmohan
Allen Lindsey Erick
Harding Miles Dillon
Newcomb Eric
Patrick Powers Jay
Reid Rosen Brandon
Ui Sharif Ehesan
Original Assignee
Arcus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcus Biosciences Inc filed Critical Arcus Biosciences Inc
Publication of MX2018008350A publication Critical patent/MX2018008350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
MX2018008350A 2016-01-08 2017-01-06 Moduladores de 5´-nucleotidasa, ecto y el uso de los mismos. MX2018008350A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276564P 2016-01-08 2016-01-08
US201662324077P 2016-04-18 2016-04-18
PCT/US2017/012587 WO2017120508A1 (en) 2016-01-08 2017-01-06 Modulators of 5'-nucleotidase, ecto and the use thereof

Publications (1)

Publication Number Publication Date
MX2018008350A true MX2018008350A (es) 2019-05-30

Family

ID=59274491

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008350A MX2018008350A (es) 2016-01-08 2017-01-06 Moduladores de 5´-nucleotidasa, ecto y el uso de los mismos.
MX2022006322A MX2022006322A (es) 2016-01-08 2018-07-05 Moduladores de 5'-nucleotidasa, ecto y el uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006322A MX2022006322A (es) 2016-01-08 2018-07-05 Moduladores de 5'-nucleotidasa, ecto y el uso de los mismos.

Country Status (29)

Country Link
US (5) US10239912B2 (enExample)
EP (2) EP4306525A3 (enExample)
JP (4) JP6920344B2 (enExample)
KR (1) KR102772803B1 (enExample)
CN (3) CN114395005B (enExample)
AU (2) AU2017206061B2 (enExample)
BR (1) BR112018013827B1 (enExample)
CA (2) CA3151595A1 (enExample)
CL (1) CL2018001845A1 (enExample)
DK (1) DK3399984T3 (enExample)
EA (1) EA038565B1 (enExample)
ES (1) ES2963759T3 (enExample)
FI (1) FI3399984T3 (enExample)
HR (1) HRP20231155T1 (enExample)
HU (1) HUE063388T2 (enExample)
IL (1) IL260260B2 (enExample)
LT (1) LT3399984T (enExample)
MX (2) MX2018008350A (enExample)
MY (1) MY204877A (enExample)
PH (1) PH12018501361A1 (enExample)
PL (1) PL3399984T3 (enExample)
PT (1) PT3399984T (enExample)
SA (1) SA518391985B1 (enExample)
SG (1) SG11201805506YA (enExample)
SI (1) SI3399984T1 (enExample)
TW (2) TW202227095A (enExample)
UA (1) UA124529C2 (enExample)
WO (1) WO2017120508A1 (enExample)
ZA (2) ZA201804350B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3151595A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
US10472364B2 (en) 2016-09-09 2019-11-12 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
CR20190268A (es) 2016-12-08 2019-07-11 Hoffmann La Roche Nuevos deribados de isoxazolil éter como pam de gaba a alfa5
EP3558998A4 (en) * 2016-12-22 2020-06-10 Calithera Biosciences, Inc. ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
BR112020006809A2 (pt) 2017-10-06 2020-10-06 Innate Pharma anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
WO2019090111A1 (en) * 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN111094317B (zh) * 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
WO2019173682A1 (en) * 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
WO2019213174A1 (en) 2018-04-30 2019-11-07 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
PT3807316T (pt) 2018-06-18 2024-07-29 Innate Pharma Composições e métodos para tratamento de cancro
US20210169911A1 (en) * 2018-08-17 2021-06-10 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Purine and pyrimidine nucleotides as ecto-5'-nucleotidase inhibitors
CN112638389A (zh) 2018-08-28 2021-04-09 江苏恒瑞医药股份有限公司 Cd73抑制剂及其治疗用途
EP3849992A4 (en) * 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
CN110885352B (zh) * 2018-09-11 2023-02-24 润佳（苏州）医药科技有限公司 Cd73抑制剂及其药学应用
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
WO2020123772A1 (en) * 2018-12-13 2020-06-18 Arcus Biosciences, Inc. Solid forms of a cd73 inhibitor and the use thereof
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
CN112955444B (zh) * 2019-01-22 2023-12-12 江苏恒瑞医药股份有限公司 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用
CN113795267A (zh) * 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
CN113905743B (zh) * 2019-03-29 2024-04-16 江苏恒瑞医药股份有限公司 Cd73抑制剂及其治疗用途
CN113874397A (zh) * 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020210938A1 (en) * 2019-04-15 2020-10-22 Bioardis Llc Quinazoline derivatives as cd73 inhibitors
WO2020210970A1 (en) * 2019-04-16 2020-10-22 Bioardis Llc Imidazotriazine derivatives as cd73 inhibitors
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
KR20220034780A (ko) * 2019-06-14 2022-03-18 써던 리서취 인스티튜트 2,4,7-치환된-7-데아자-2'-데옥시-2'-플루오로아라비노실 뉴클레오사이드 및 뉴클레오타이드 전구약물 및 이의 용도
JP7557522B2 (ja) 2019-07-16 2024-09-27 オリック ファーマシューティカルズ，インク． Ｃｄ７３阻害剤
WO2021040356A1 (en) * 2019-08-23 2021-03-04 Kainos Medicine, Inc. C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition
WO2021041319A1 (en) * 2019-08-29 2021-03-04 Eli Lilly And Company Crystalline forms of a cd73 inhibitor
EP4051688B1 (en) * 2019-10-30 2025-04-23 Oric Pharmaceuticals, Inc. Cd73 inhibitors
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN115298165B (zh) 2020-03-19 2024-09-17 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
WO2021257643A1 (en) * 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022007677A1 (zh) * 2020-07-07 2022-01-13 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022052886A1 (zh) * 2020-09-08 2022-03-17 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022095953A1 (zh) * 2020-11-05 2022-05-12 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CA3197340A1 (en) * 2020-11-05 2022-05-12 Xuejun Zhang Cd73 inhibitor and use thereof
EP4251633A4 (en) * 2020-11-25 2024-09-25 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF
US20240024346A1 (en) * 2020-11-25 2024-01-25 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
CN116783196A (zh) * 2020-12-29 2023-09-19 浙江春禾医药科技有限公司 A3腺苷受体激动剂及其制备方法和用途
EP4353732A1 (en) 2021-05-11 2024-04-17 Xizang Haisco Pharmaceutical Co., Ltd. Small molecular cd73 antagonist and use thereof
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
US20240226115A1 (en) 2021-05-21 2024-07-11 Arcus Biosciences, Inc. Axl inhibitor compounds
WO2023061319A1 (zh) * 2021-10-11 2023-04-20 南京明德新药研发有限公司 三并环杂环衍生物
CA3235405A1 (en) * 2021-10-26 2023-05-04 Omar MOUKHA-CHAFIQ Development of novel clofarabine analogs for cancer therapy
AU2022376961A1 (en) 2021-10-29 2024-05-16 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
US20250179176A1 (en) 2022-05-02 2025-06-05 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
EP4558501A1 (en) 2022-07-20 2025-05-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN117466964A (zh) * 2022-07-21 2024-01-30 南京烁慧医药科技有限公司 双磷酸核苷类化合物及其制备方法
KR20250065402A (ko) 2022-09-14 2025-05-12 아르커스 바이오사이언시즈 인코포레이티드 에트루마데난트 분산체
WO2024076873A1 (en) * 2022-10-03 2024-04-11 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
US20240140979A1 (en) * 2022-10-03 2024-05-02 Teon Therapeutics, Inc. Heterocyclic inhibitors of cd73 for treatment of disease
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
TW202428286A (zh) 2022-10-20 2024-07-16 美商阿克思生物科學有限公司 Ｃｄ７３化合物之凍乾配方
WO2024233360A1 (en) 2023-05-05 2024-11-14 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN117924394A (zh) * 2023-09-05 2024-04-26 厦门大学 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076299A1 (en) 2023-10-06 2025-04-10 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
WO2025113498A1 (zh) * 2023-12-01 2025-06-05 无锡和誉生物医药科技有限公司 一种cd73抑制剂碱式盐及其制备方法和应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
KR100560182B1 (ko) * 1996-10-09 2006-03-13 파마셋 인코포레이티드 비스포스포네이트 화합물
WO2002048165A2 (en) 2000-12-15 2002-06-20 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
WO2012032513A1 (en) * 2010-09-07 2012-03-15 Bar-Ilan University Boranophosphate derivatives for the treatment of osteoarthritis
WO2013132489A1 (en) 2012-03-05 2013-09-12 Bar-Ilan University Nucleoside 5'-phosphorothioate analogues and uses thereof
EP2846788A1 (en) 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
FR3011240A1 (fr) * 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
ES3040431T3 (en) * 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
MA42659A (fr) 2015-08-17 2018-06-27 Lupin Ltd Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
UY37062A (es) 2016-01-08 2017-08-31 Syngenta Participations Ag Derivados de aryl oxadiazol fungicidas
CA3151595A1 (en) 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
WO2019173682A1 (en) 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
WO2020123772A1 (en) 2018-12-13 2020-06-18 Arcus Biosciences, Inc. Solid forms of a cd73 inhibitor and the use thereof
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
WO2021257643A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Also Published As

Publication number Publication date
CN108697719A (zh) 2018-10-23
CA3009196A1 (en) 2017-07-13
JP7698677B2 (ja) 2025-06-25
TWI744274B (zh) 2021-11-01
CN114395005A (zh) 2022-04-26
AU2017206061A1 (en) 2018-07-19
EP3399984A1 (en) 2018-11-14
US11667662B2 (en) 2023-06-06
IL260260B2 (en) 2024-01-01
JP7322104B2 (ja) 2023-08-07
US20210371449A1 (en) 2021-12-02
CN119912510A (zh) 2025-05-02
SG11201805506YA (en) 2018-07-30
MX2022006322A (es) 2022-06-22
EP3399984B1 (en) 2023-09-06
KR20180100638A (ko) 2018-09-11
AU2017206061A8 (en) 2018-07-26
US11001603B2 (en) 2021-05-11
JP6920344B2 (ja) 2021-08-18
US20190309010A1 (en) 2019-10-10
KR102772803B1 (ko) 2025-02-24
DK3399984T3 (da) 2023-11-13
CL2018001845A1 (es) 2018-12-07
JP2025123371A (ja) 2025-08-22
US20170267710A1 (en) 2017-09-21
AU2023201288B2 (en) 2025-02-20
EP4306525A2 (en) 2024-01-17
SA518391985B1 (ar) 2022-12-19
CN108697719B (zh) 2024-03-19
SI3399984T1 (sl) 2024-01-31
PT3399984T (pt) 2023-11-21
AU2017206061B2 (en) 2022-12-15
AU2023201288A1 (en) 2023-04-06
US20210002322A1 (en) 2021-01-07
ES2963759T3 (es) 2024-04-01
IL260260B1 (en) 2023-09-01
EA201891583A1 (ru) 2019-01-31
PL3399984T3 (pl) 2024-02-19
FI3399984T3 (fi) 2023-11-10
UA124529C2 (uk) 2021-10-05
US10239912B2 (en) 2019-03-26
ZA202209472B (en) 2023-06-28
US12459967B2 (en) 2025-11-04
HRP20231155T1 (hr) 2024-01-05
JP2019501223A (ja) 2019-01-17
US10981944B2 (en) 2021-04-20
ZA201804350B (en) 2023-11-29
JP2023129628A (ja) 2023-09-14
BR112018013827B1 (pt) 2024-02-20
EA038565B1 (ru) 2021-09-15
NZ744128A (en) 2024-10-25
PH12018501361A1 (en) 2019-02-27
US20240352057A1 (en) 2024-10-24
TW201805006A (zh) 2018-02-16
HUE063388T2 (hu) 2024-01-28
JP2021167351A (ja) 2021-10-21
WO2017120508A1 (en) 2017-07-13
BR112018013827A2 (pt) 2018-12-11
WO2017120508A8 (en) 2018-07-05
LT3399984T (lt) 2023-11-10
TW202227095A (zh) 2022-07-16
MY204877A (en) 2024-09-20
CN114395005B (zh) 2024-12-31
IL260260A (en) 2018-07-31
EP3399984A4 (en) 2020-01-01
CA3151595A1 (en) 2017-07-13
CA3009196C (en) 2022-05-31
EP4306525A3 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
MX2022006322A (es) Moduladores de 5'-nucleotidasa, ecto y el uso de los mismos.
PH12017500604A1 (en) Immunoregulatory agents
PH12017500629A1 (en) Immuniregulatory agents
MX2017005462A (es) Agentes inmunorreguladores.
MX2016015610A (es) Agentes inmunorreguladores.
PH12020500252A1 (en) Compounds as modulators of ror gamma
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
WO2016172658A3 (en) Microbiome regulators and related uses thereof
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MY195244A (en) Muscarinic Agonists
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
WO2019028309A1 (en) AZAINDOLES AND THEIR METHODS OF USE
GB2553686A (en) Ethynylxanthines, preparation and use as calcium ion channel modulators